Clinical Trials Directory

Trials / Unknown

UnknownNCT04625322

HCV Treatment Initiation During Acute Psychiatric Admission

INSPIRE: Interventions for Screening and Treatment of Psychiatric Inpatients With HCV Resulting in Elimination

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
54 (estimated)
Sponsor
University Health Network, Toronto · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Hepatitis C virus (HCV) disproportionally affects certain populations, including those facing substance use and mental health challenges. In the past, many individuals with mental illness were not treated due to the psychiatric side-effects of interferon. However, the development of highly effective, direct-acting antivirals (DAA) has revolutionized HCV treatment such that cure rates are \>95% with 8-12 weeks of simple, safe, and well-tolerated therapy. A recent systematic review reported that across 13 North American studies, HCV prevalence among people admitted to psychiatric hospitals was a staggering 17.4% (13.2-22.6%). Despite these concerning figures, mental health facilities have not been a focus of HCV elimination efforts to date. The Centre for Addiction and Mental Health (CAMH) in Toronto is the largest mental health facility in Canada, with a psychiatric emergency department seeing \~35 patients per day with many admitted to the acute psychiatric units for safety and stabilization. Currently, psychiatric patients screened for HCV at CAMH have a 75% 'no show' rate at the Toronto Centre for Liver Disease (TCLD), which is located less than 5km away, suggesting that referral upon discharge is ineffective. This study will be the first trial to evaluate whether it would be feasible and beneficial to initiate treatment during an acute psychiatric admission rather than referring to specialty upon discharge. The combination of broad HCV screening with rapid linkage to treatment has led to successful elimination of HCV within defined populations, so-called micro-elimination. The investigators hypothesize that HCV treatment can be effectively delivered by providers in psychiatric care facilities, which will improve treatment uptake over traditional referral models.

Conditions

Interventions

TypeNameDescription
OTHERHCV care provided by hospitalist during acute psychiatric admissionHCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH

Timeline

Start date
2022-04-19
Primary completion
2023-04-01
Completion
2023-04-01
First posted
2020-11-12
Last updated
2022-05-05

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT04625322. Inclusion in this directory is not an endorsement.